Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
Background: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-blind study. Methods: Patients with untreated advanc...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fdbc7c412b564497a8805b161236dd76 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fdbc7c412b564497a8805b161236dd76 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fdbc7c412b564497a8805b161236dd762021-11-20T05:11:24ZEfficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study2589-537010.1016/j.eclinm.2021.101187https://doaj.org/article/fdbc7c412b564497a8805b161236dd762021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589537021004685https://doaj.org/toc/2589-5370Background: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-blind study. Methods: Patients with untreated advanced or recurrent NSCLC were randomized (1:1 ratio) to receive either MIL60 or bevacizumab in combination with paclitaxel/carboplatin. Patients with non-progressive disease continued maintenance single-agent MIL60 until disease progression, or intolerable toxicity. The primary endpoint was the 12-week objective response rates (ORR12) by independent review committee (IRC) using RECIST 1.1. Bioequivalence was established if the ORR ratio located between 0.75 and 1/0.75. The trial was registered with clinicaltrials.gov (NCT03196986). Findings: Between Aug 23, 2017, and May 8, 2019, 517 patients were randomly assigned to MIL60 group (n=257) and bevacizumab group (n=260). In the full analysis set (FAS) population including all randomized and evaluable patients who received at least one dose of MIL60 or bevacizumab, the ORR12 in MIL60 group and bevacizumab group were 48.6% and 43.1%, respectively. The ORR ratio of these two groups were 1.14 (90% CI 0.97-1.33), which fell within the pre-specified equivalence boundaries (0.75-1/0.75). The median DOR was 5.7 months (95% CI 4.5-6.2) for MIL60 and 5.6 months (95% CI 4.3-6.4) for bevacizumab. No significant difference was noted in median PFS (7.2 vs. 8.1 months; HR 1.01, 95% CI 0.78-1.30, p=0.9606) and OS (19.3 vs. 16.3 months; HR 0.81, 95% CI 0.64-1.02, p=0.0755). Safety and tolerability profiles were similar between the two groups. No patient detected positive for Anti-drug antibody (ADA). Interpretation: The efficacy, safety and immunogenicity of MIL60 were similar with bevacizumab, providing an alternative treatment option for advanced or recurrent non-squamous NSCLC. Funding: This study was sponsored by Betta Pharmaceutical Co., Ltd.Rui WanXiaorong DongQun ChenYan YuShujun YangXiaochun ZhangGuojun ZhangYueyin PanSanyuan SunChengzhi ZhouWei HongHui ZhaoLei YangLinian HuangRong WuAimin ZangRui MaLin WuDongqing LvXiuhua FuJianguo HanWenxin LiJianchun DuanKai WangOu JiangYinglan ChenZhongliang GuoHongjun GaoJuyi WenShubin WangEnfeng ZhaoGaofeng LiLu YueLi LiangAiping ZengXiaoshan WangYuxi ZhuHongming PanZhaoxia DaiWeineng FengGuofang ZhaoChuan LinChong LiNa LiYangyi BaoYinyin LiYanjun SuMin ZhaoHaohui FangYulong ZhuYu ZhangLieming DingYang WangXiaobin YuanJie WangElsevierarticleMIL60biosimilarbevacizumabequivalencenon-squamous NSCLCMedicine (General)R5-920ENEClinicalMedicine, Vol 42, Iss , Pp 101187- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
MIL60 biosimilar bevacizumab equivalence non-squamous NSCLC Medicine (General) R5-920 |
| spellingShingle |
MIL60 biosimilar bevacizumab equivalence non-squamous NSCLC Medicine (General) R5-920 Rui Wan Xiaorong Dong Qun Chen Yan Yu Shujun Yang Xiaochun Zhang Guojun Zhang Yueyin Pan Sanyuan Sun Chengzhi Zhou Wei Hong Hui Zhao Lei Yang Linian Huang Rong Wu Aimin Zang Rui Ma Lin Wu Dongqing Lv Xiuhua Fu Jianguo Han Wenxin Li Jianchun Duan Kai Wang Ou Jiang Yinglan Chen Zhongliang Guo Hongjun Gao Juyi Wen Shubin Wang Enfeng Zhao Gaofeng Li Lu Yue Li Liang Aiping Zeng Xiaoshan Wang Yuxi Zhu Hongming Pan Zhaoxia Dai Weineng Feng Guofang Zhao Chuan Lin Chong Li Na Li Yangyi Bao Yinyin Li Yanjun Su Min Zhao Haohui Fang Yulong Zhu Yu Zhang Lieming Ding Yang Wang Xiaobin Yuan Jie Wang Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| description |
Background: We compared the efficacy, safety, and immunogenicity of MIL60 with reference bevacizumab as first-line treatment in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in this phase 3, randomized, double-blind study. Methods: Patients with untreated advanced or recurrent NSCLC were randomized (1:1 ratio) to receive either MIL60 or bevacizumab in combination with paclitaxel/carboplatin. Patients with non-progressive disease continued maintenance single-agent MIL60 until disease progression, or intolerable toxicity. The primary endpoint was the 12-week objective response rates (ORR12) by independent review committee (IRC) using RECIST 1.1. Bioequivalence was established if the ORR ratio located between 0.75 and 1/0.75. The trial was registered with clinicaltrials.gov (NCT03196986). Findings: Between Aug 23, 2017, and May 8, 2019, 517 patients were randomly assigned to MIL60 group (n=257) and bevacizumab group (n=260). In the full analysis set (FAS) population including all randomized and evaluable patients who received at least one dose of MIL60 or bevacizumab, the ORR12 in MIL60 group and bevacizumab group were 48.6% and 43.1%, respectively. The ORR ratio of these two groups were 1.14 (90% CI 0.97-1.33), which fell within the pre-specified equivalence boundaries (0.75-1/0.75). The median DOR was 5.7 months (95% CI 4.5-6.2) for MIL60 and 5.6 months (95% CI 4.3-6.4) for bevacizumab. No significant difference was noted in median PFS (7.2 vs. 8.1 months; HR 1.01, 95% CI 0.78-1.30, p=0.9606) and OS (19.3 vs. 16.3 months; HR 0.81, 95% CI 0.64-1.02, p=0.0755). Safety and tolerability profiles were similar between the two groups. No patient detected positive for Anti-drug antibody (ADA). Interpretation: The efficacy, safety and immunogenicity of MIL60 were similar with bevacizumab, providing an alternative treatment option for advanced or recurrent non-squamous NSCLC. Funding: This study was sponsored by Betta Pharmaceutical Co., Ltd. |
| format |
article |
| author |
Rui Wan Xiaorong Dong Qun Chen Yan Yu Shujun Yang Xiaochun Zhang Guojun Zhang Yueyin Pan Sanyuan Sun Chengzhi Zhou Wei Hong Hui Zhao Lei Yang Linian Huang Rong Wu Aimin Zang Rui Ma Lin Wu Dongqing Lv Xiuhua Fu Jianguo Han Wenxin Li Jianchun Duan Kai Wang Ou Jiang Yinglan Chen Zhongliang Guo Hongjun Gao Juyi Wen Shubin Wang Enfeng Zhao Gaofeng Li Lu Yue Li Liang Aiping Zeng Xiaoshan Wang Yuxi Zhu Hongming Pan Zhaoxia Dai Weineng Feng Guofang Zhao Chuan Lin Chong Li Na Li Yangyi Bao Yinyin Li Yanjun Su Min Zhao Haohui Fang Yulong Zhu Yu Zhang Lieming Ding Yang Wang Xiaobin Yuan Jie Wang |
| author_facet |
Rui Wan Xiaorong Dong Qun Chen Yan Yu Shujun Yang Xiaochun Zhang Guojun Zhang Yueyin Pan Sanyuan Sun Chengzhi Zhou Wei Hong Hui Zhao Lei Yang Linian Huang Rong Wu Aimin Zang Rui Ma Lin Wu Dongqing Lv Xiuhua Fu Jianguo Han Wenxin Li Jianchun Duan Kai Wang Ou Jiang Yinglan Chen Zhongliang Guo Hongjun Gao Juyi Wen Shubin Wang Enfeng Zhao Gaofeng Li Lu Yue Li Liang Aiping Zeng Xiaoshan Wang Yuxi Zhu Hongming Pan Zhaoxia Dai Weineng Feng Guofang Zhao Chuan Lin Chong Li Na Li Yangyi Bao Yinyin Li Yanjun Su Min Zhao Haohui Fang Yulong Zhu Yu Zhang Lieming Ding Yang Wang Xiaobin Yuan Jie Wang |
| author_sort |
Rui Wan |
| title |
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| title_short |
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| title_full |
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| title_fullStr |
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| title_full_unstemmed |
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| title_sort |
efficacy and safety of mil60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/fdbc7c412b564497a8805b161236dd76 |
| work_keys_str_mv |
AT ruiwan efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT xiaorongdong efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT qunchen efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yanyu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT shujunyang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT xiaochunzhang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT guojunzhang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yueyinpan efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT sanyuansun efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT chengzhizhou efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT weihong efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT huizhao efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT leiyang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT linianhuang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT rongwu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT aiminzang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT ruima efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT linwu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT dongqinglv efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT xiuhuafu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT jianguohan efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT wenxinli efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT jianchunduan efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT kaiwang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT oujiang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yinglanchen efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT zhongliangguo efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT hongjungao efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT juyiwen efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT shubinwang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT enfengzhao efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT gaofengli efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT luyue efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT liliang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT aipingzeng efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT xiaoshanwang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yuxizhu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT hongmingpan efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT zhaoxiadai efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT weinengfeng efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT guofangzhao efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT chuanlin efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT chongli efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT nali efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yangyibao efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yinyinli efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yanjunsu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT minzhao efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT haohuifang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yulongzhu efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yuzhang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT liemingding efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT yangwang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT xiaobinyuan efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy AT jiewang efficacyandsafetyofmil60comparedwithbevacizumabinadvancedorrecurrentnonsquamousnonsmallcelllungcanceraphase3randomizeddoubleblindstudy |
| _version_ |
1718419578551271424 |